TGen to Conduct Phase I Study of Prolexys Anti-Cancer Drug | GenomeWeb
Prolexys Pharmaceuticals yesterday announced the start of its first human trials of PRLX 93936, a potential anti-cancer compound.
 
Among the study centers performing the phase I studies of this erastin analog is TGen Clinical Research. At TGen and the other study sites, the safety, efficacy, and pharmocodynamic properties of PRLX 93936 will be evaluated in patients with advanced solid tumors.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Startup companies are taking on personalized medicine, CNET reports.

Bruce Booth writes at Life Sci VC that biotech clusters like Boston and San Francisco are getting even more consolidated.

The Verge speaks with Mark and Scott Kelly, who are the subjects of NASA's Twin Study.

In Genome Biology this week: genes linked to Hirschsprung disease, structural variant patterns in autism, and more.